1786 related articles for article (PubMed ID: 16162664)
1. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.
DeRyke CA; Kuti JL; Nicolau DP
Pharmacotherapy; 2007 Mar; 27(3):333-42. PubMed ID: 17316145
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
Frei CR; Burgess DS
Clin Ther; 2008 Dec; 30(12):2335-41. PubMed ID: 19167592
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.
Wang H; Zhang B; Ni Y; Kuti JL; Chen B; Chen M; Nicolau DP
Int J Antimicrob Agents; 2007 Nov; 30(5):452-7. PubMed ID: 17646088
[TBL] [Abstract][Full Text] [Related]
7. Continuous infusion beta-lactams for intensive care unit pulmonary infections.
Frei CR; Burgess DS
Clin Microbiol Infect; 2005 May; 11(5):418-21. PubMed ID: 15819874
[TBL] [Abstract][Full Text] [Related]
8. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.
Masterton RG; Kuti JL; Turner PJ; Nicolau DP
J Antimicrob Chemother; 2005 Jan; 55(1):71-7. PubMed ID: 15574471
[TBL] [Abstract][Full Text] [Related]
9. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
Zarakolu P; Hasçelik G; Unal S
Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
[TBL] [Abstract][Full Text] [Related]
10. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.
Crandon JL; Kuti JL; Jones RN; Nicolau DP
Ann Pharmacother; 2009 Feb; 43(2):220-7. PubMed ID: 19193582
[TBL] [Abstract][Full Text] [Related]
13. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007).
Patzer JA; Dzierzanowska D; Turner PJ
J Antimicrob Chemother; 2008 Aug; 62(2):369-75. PubMed ID: 18445575
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
[TBL] [Abstract][Full Text] [Related]
16. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
[TBL] [Abstract][Full Text] [Related]
17. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
Chen MJ; Wang H;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program.
Koomanachai P; Crandon JL; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2009 Apr; 33(4):348-53. PubMed ID: 19091515
[TBL] [Abstract][Full Text] [Related]
19. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics].
Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H
Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430
[TBL] [Abstract][Full Text] [Related]
20. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
Ellis JM; Kuti JL; Nicolau DP
Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
